Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4808 - The use of PD-1 inhibitors for the advanced melanoma of esophagus

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Immunotherapy

Tumour Site

Melanoma

Presenters

Lili Mao

Citation

Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289

Authors

L. Mao, X. Wang, L. Si, Y. Kong, Z. Chi, X. Sheng, C. Cui, B. Lian, B. Tang, X. Yan, J. Guo

Author affiliations

  • Renal Cancer And Melanoma, Beijing Cancer Hospital, 100141 - Beijing/CN
More

Resources

Abstract 4808

Background

Melanoma of esophagus (ME) is a rare type of melanoma, accounting for <3% of cases. Patients with advanced melanoma of esophagus origin, tend to have lower response rates on traditional therapies. Thus, we report our experience with 11 patients with advanced esophageal melanoma who received PD-1 inhibitors.

Methods

A retrospective analysis of 77 patients with advanced ME were conducted from the database of Peking University Cancer Hospital between Jan 2008 and Sep 2017. We collected the clinical data and assessed objective response rates (ORR) and progression–free survival (PFS). The data cutoff date was Jan 1st 2018.

Results

We identified the 77 patients were unresectable or metastatic esophageal melanomas. The Median age was 57, with 67.5% being male. 78% patients had history of esophagectomy and 64 patients had received prior systemic therapy. There were 8 (10.4%) patients harbored C-KIT mutations and 5 (6.5%) harbored BRAF. We divided the patients into 3 cohorts according to different treatments: Chemotherapy (C: 8 DTIC/26 TMZ/ 23 PTX; 57 cases), Targeted therapy (T: 6 imatinib/3 vemurafenib; 9 cases) or PD-1 inhibitors (P, 11 cases). The PFS were 3.0 and 4.2 months with limited ORR of 5.7% and 25.0% respectively for C and T cohort. In the P cohort, 7/11 patients (63.6%) achieved PR and other 3 remained SD > 4+ months. The PFS for the P cohort was 13.0+ months. Toxicities were as expected and were usually grade 1or 2.

Conclusions

Although this cohort of patients was small, it was the largest report for now. To our knowledge this is also the first report of outcomes of PD-1 inhibitors in advanced esophageal melanomas. The dramatic response appears to be an available option for patients with advanced esophageal melanomas.

Clinical trial identification

Legal entity responsible for the study

Beijing Cancer Hospital.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.